Clinical Trials

Showing trials with last updates posted in 2022.

NCT01835145 | COMPLETED | PHASE2
47 participants

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2022-08-04
Start Date:
2013-07-31
Completion:
2016-10-21
Conditions
  • Recurrent Uveal Melanoma
  • Stage III Uveal Melanoma AJCC v7
  • Stage IIIA Uveal Melanoma AJCC v7
  • Stage IIIB Uveal Melanoma AJCC v7
  • Stage IIIC Uveal Melanoma AJCC v7
  • Stage IV Uveal Melanoma AJCC v7
Interventions
  • DRUG
  • OTHER
NCT01253070 | COMPLETED | PHASE2
54 participants

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2022-08-04
Start Date:
2011-04-01
Completion:
2014-10-31
Conditions
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
  • Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
  • Acute Promyelocytic Leukemia With PML-RARA
  • FLT3 Gene Mutation
  • Therapy-Related Acute Myeloid Leukemia
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
NCT01229943 | COMPLETED | PHASE2
150 participants

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2022-08-04
Start Date:
2010-10-15
Completion:
2014-09-01
Conditions
  • Advanced Pancreatic Neuroendocrine Tumor
  • Locally Advanced Pancreatic Neuroendocrine Tumor
  • Pancreatic Gastrinoma
  • Pancreatic Neuroendocrine Tumor G1
  • Pancreatic Neuroendocrine Tumor G2
  • Pancreatic Vipoma
Interventions
  • BIOLOGICAL
  • DRUG
NCT01168219 | COMPLETED | PHASE2
68 participants

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2022-08-04
Start Date:
2010-07-15
Completion:
2015-11-14
Conditions
  • Acute Myeloid Leukemia
  • Adult Acute Megakaryoblastic Leukemia
  • Adult Acute Monoblastic Leukemia
  • Adult Acute Monocytic Leukemia
  • Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
  • Adult Acute Myeloid Leukemia With Maturation
  • Adult Acute Myeloid Leukemia With Minimal Differentiation
  • Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
  • Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
  • Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL
  • Adult Acute Myeloid Leukemia Without Maturation
  • Adult Acute Myelomonocytic Leukemia
  • Adult Erythroleukemia
  • Adult Pure Erythroid Leukemia
  • Alkylating Agent-Related Acute Myeloid Leukemia
  • de Novo Myelodysplastic Syndrome
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome With Excess Blasts
  • Recurrent Adult Acute Myeloid Leukemia
  • Secondary Myelodysplastic Syndrome
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • DRUG
  • OTHER
Previous
Sorted by latest updates
Next
Showing 40 trials per page